BCDA

BioCardia, Inc.

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0000925741 Biotech & Drug Discovery

$0.9000 −0.02 (−2.17%)

Oct 26 4:00 PM ET · prev $0.9200

Market cap

$14.1M

Nano cap

Consensus

Buy

88% Buy or better · 8 analysts

Median target

$15.50

+1622% · range $6.00–25.00

Next earnings

Nov 11

in 15 days · EPS est. −$0.15

1 year

−31.3%

from $1.31 · Oct 27

30 days

−13.5%

from $1.04

52-week range

$0.7700–1.47

−39% from high · low Jul 29

Avg volume 20D

140.0K

Oct 19 spike 438.9K

Short interest

🔒 Subscribers only

Insider net

+$167.0K

2 buyers · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BULLISH 10 reports · 90 days

Balance 0 bearish · 4 bullish · 6 neutral oldest → newest, height = score

Avg score

·High conf. 3/10 ·Next Earnings date, Nov 11, 2026

Strongest BULLISH BioCardia announced FDA acceptance of its De Novo pre-submission package for the Helix catheter, a…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Apr 20 BioCardia announced a positive outcome from its regulatory consultat…
B Jun 17 to Jun 23 4 days of insider buys: $105.6K by 2 insiders, avg $0.9473
B Jul 8 to Jul 17 6 days of insider buys: $16.6K by 1 insider, avg $0.9352
B Aug 13 to Aug 17 2 days of insider buys: $6.8K by 1 insider, avg $0.9274
B Sep 23 to Sep 29 2 days of insider buys: $3.0K by 1 insider, avg $1.04
X Sep 30 Short interest falls 28.3% to 619.2K
B Oct 15 to Oct 16 2 days of insider buys: $475.00 by 1 insider, avg $0.9500
E Oct 19 FDA: BioCardia Announces FDA Acceptance of De Novo Pre-Submissi…

Signal stack

Where each data set points today.

InsidersBULLISH

2 insiders bought $167.0K at an average $0.9539. No open-market sales. Price is 6% below their cost.
InstitutionsMIXED

Q2 2026: 1 added (0 new), 2 trimmed or exited.
AnalystsBULLISH

7 of 8 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$0.170 → −$0.150 over 90 days. 1 up, 0 down in 30 days.
TrendDOWNTREND

15% below its 50-day average.
SocialQUIET

No Reddit mentions this week. Last mention Oct 6.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
GEODE CAPITAL MANAGEMENT, LLC	TRIM	66,664	$82.7K
COMMONWEALTH EQUITY SERVICES, LLC	ADD	23,383	$29.0K
CITADEL ADVISORS LLC	TRIM	22,956	$28.5K
GEODE CAPITAL MANAGEMENT, LLC	ADD	94,287	$114.1K
VANGUARD GROUP INC	ADD	135,561	$169.5K
GEODE CAPITAL MANAGEMENT, LLC	ADD	66,003	$82.5K
UBS Group AG	TRIM	4,423	$5.5K
OSAIC HOLDINGS, INC.	NEAR_EXIT	1	$1.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts

Buy 88% rate it Buy or better

Strong Buy2Buy5Hold1Sell0Strong Sell0

12-month targets · 2 analysts

$0.9000 $6.00 $15.50 $25.00

Price is below the lowest target. Median implies +1622%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 24, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
Jun 9, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy

Insider ledger

Form 4

$167.0K

bought · 2 insiders

sold · 0 insiders

−5.7%

vs their $0.9539 cost

Date	Insider	Type	Value
Oct 16, 2026	Altman Peter President and CEO	BUY	$285.00
Oct 15, 2026	Altman Peter President and CEO	BUY	$190.00
Sep 29, 2026	Altman Peter President and CEO	BUY	$1.0K
Sep 23, 2026	Altman Peter President and CEO	BUY	$2.0K
Sep 3, 2026	Altman Peter President and CEO	BUY	$872.00
Aug 17, 2026	Altman Peter President and CEO	BUY	$5.0K
Aug 13, 2026	Altman Peter President and CEO	BUY	$1.7K
Jul 29, 2026	Altman Peter President and CEO	BUY	$3.9K

Earnings setup

Estimates

Nov 11

reports in 15 days

−$0.15

EPS estimate, this quarter

+12%

estimate change, 90 days

1↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.170

90d

−$0.180

60d

−$0.180

30d

−$0.180

−$0.150

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.15	-$0.15–-$0.15	+16.7%	$0.00
Next Q	-$0.21	-$0.21–-$0.21	-5.0%	$0.00
Current FY	-$0.71	-$0.71–-$0.71	+6.6%	$0.00
Next FY	-$0.58	-$0.58–-$0.58	+3.3%	$0.00

Short side

FINRA· Oct 15, 2026

🔒 Subscribers only

shares short

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 19, 2026 SEC

BioCardia announced FDA acceptance of its De Novo pre-submission package for the Helix catheter, a transendocardial…

8-K — Impact 6/10

Oct 19, 2026 Press

BioCardia announced FDA acceptance of its De Novo pre-submission package for the Helix transendocardial delivery…

Impact 6/10

Oct 19, 2026 FDA

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter

SUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader

Oct 16, 2026 Insider

Altman Peter bought 300 shares

President and CEO @ $0.9500 ($285.00)

Oct 15, 2026 Insider

Altman Peter bought 200 shares

President and CEO @ $0.9500 ($190.00)

Oct 7, 2026 SEC

BioCardia filed an 8-K announcing a poster presentation of the CardiAMP HF II trial design at the HFSA Annual…

8-K — Impact 3/10

Oct 1, 2026 SEC

BioCardia filed a revised De Novo pre-submission with the FDA CDRH for its Helix Catheter, a device for therapeutic…